A recent commentary in New Zealand’s Newsroom, The nicotine pouch fix is a false promise, by Drs Janet Hoek, George Leigh and Andrew Waa, questions whether legalising nicotine pouches would reduce demand for illicit tobacco.
The authors raise legitimate concerns about youth exposure, nicotine dependence and the limitations of relying on alternative products to address illegal cigarette sales. Their argument also raises a broader question: does the absence of an approved smoking-cessation claim mean nicotine pouches have no potential role in reducing smoking-related harm?
Evidence from the United States suggests that these questions require separate consideration.
Smoking Cessation and Product Substitution
Nicotine pouches are generally marketed as consumer nicotine products rather than licensed smoking-cessation medicines. That distinction is important, but it does not establish whether adults who smoke might replace cigarettes with them.
In January 2025, the US Food and Drug Administration authorised 20 ZYN nicotine pouch products following an extensive scientific review.
The agency found that these specific products contained substantially lower levels of harmful constituents than cigarettes and most smokeless tobacco products. Its assessment also considered evidence that a substantial proportion of adult cigarette or smokeless tobacco users in an applicant-submitted study had switched completely to the pouches.
This finding supports the potential for product substitution. It does not establish that nicotine pouches are effective cessation medicines or that expanding their availability would necessarily reduce smoking prevalence across an entire population.
In June 2026, the FDA went further, permitting the same 20 products to carry a specified reduced-risk claim concerning several serious smoking-related diseases when used instead of cigarettes.
These decisions demonstrate that a product can receive regulatory recognition for its potential public-health benefits without being authorised as a therapeutic cessation aid.
What the Evidence Means for New Zealand
New Zealand’s illicit tobacco market presents a different policy challenge. Legal access to nicotine pouches would not, by itself, resolve tobacco smuggling, excise avoidance or weaknesses in enforcement. The authors are right to question claims that introducing another nicotine product would automatically reduce illegal cigarette sales. However, the continued existence of illicit tobacco markets does not establish that non-combustible alternatives cannot contribute to smoking reduction.
These outcomes operate through different mechanisms. Product substitution concerns whether individual smokers replace cigarettes with another product. Illicit-market reduction depends on broader factors, including prices, consumer demand, enforcement and access to legal supply.
Sweden provides relevant experience with oral tobacco products and declining smoking prevalence. Its experience supports examining the potential contribution of substitution, although it cannot establish how nicotine pouch legalisation would affect New Zealand’s illicit market.
The appropriate policy assessment would therefore consider smoking behaviour and illicit trade separately, while investigating how they interact.
Youth Protection and Proportionate Regulation
Concerns about youth uptake remain central to this debate. Nicotine is addictive, and products that appeal to young people or encourage initiation among non-users present genuine public-health risks.
The FDA’s authorisations do not remove these concerns. They apply to specific products and include marketing restrictions and post-market monitoring.
The agency’s decisions also reflect a population-level assessment that considers potential benefits to adults who switch completely alongside risks to young people and non-users. For New Zealand, the relevant question is whether a carefully regulated nicotine pouch market could improve health outcomes compared with continued restrictions.
Answering that question requires evidence on adult switching, youth initiation, dual use and the potential consequences for legal and illicit markets.
The Newsroom authors are right that nicotine pouches should not be presented as a simple solution to illegal tobacco sales. Yet the FDA’s findings show why their potential role in reducing exposure to cigarette smoke deserves independent consideration.
For GINN, sound regulation should recognise both realities. Youth protection and effective enforcement are essential, while differences in product risk and the potential benefits of complete switching should remain part of the evidence assessment.
The objective is to determine which regulatory approach produces better public-health outcomes, rather than assuming that either unrestricted access or continued prohibition will achieve them.
Sources
- Hoek, J., Leigh, G., & Waa, A. (15 November 2026). The nicotine pouch fix is a false promise. Newsroom, New Zealand.
- US Food and Drug Administration (16 January 2025). FDA Authorizes Marketing of 20 ZYN Nicotine Pouch Products after Extensive Scientific Review.
- US Food and Drug Administration (30 June 2026). FDA Authorizes 20 ZYN Nicotine Pouches to Be Marketed with Specific Modified Risk Claim.
- Patterns of Smoking and Snus Use in Sweden: Implications for Public Health. International Journal of Environmental Research and Public Health.







